Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed first‑participant dosing in an Australia Phase I/II study today. Preclinical data show strong inhibition in tumor cells and xenograft models with diverse RAS mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic, non‑small‑cell lung and colorectal cancers, and report favorable pharmacokinetics and safety.

2026-11-10

Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed first‑participant dosing in an Australia Phase I/II study today. Preclinical data show strong inhibition in tumor cells and xenograft models with diverse RAS mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic, non‑small‑cell lung and colorectal cancers, and report favorable pharmacokinetics and safety.

其他消息
2026-11-10

亞股 1. 中國上證綜指11月9日(週一)收盤上漲11.61點,漲幅:0.32%,報3660.79點; 2. 中國深證成指11月9日(週一)收盤下跌30.29點,跌幅:0.27%,報11145.49點; 3. 中國滬深300指數11月9日(週一)收盤上漲1.83點,漲幅:0.05%,報4056.11點; 4. 中國創業板指數11月9日(週一)收盤下跌6.67點,跌幅:0.27%,報2458.56點; 5. 中國科創50指數11月9日(週一)收盤上漲3.76點,漲幅:0.30%,報1256.96點; 6. 香港恆生指數11月9日(週一)收盤下跌32.91點,跌幅0.13%,報24448.95點; 7. 香港恆生科技指數11月9日(週一)收盤下跌37.5點,跌幅0.92%,報4040.73點。 歐股 1. 德國DAX30指數11月9日(週一)收盤上漲488.43點,漲幅1.89%,報26282.55點; 2. 英國富時100指數11月9日(週一)收盤上漲114.46點,漲幅1.07%,報10788.40點; 3. 法國CAC40指數11月9日(週一)收盤上漲94.30點,漲幅1.16%,報

2026-11-10

At its Q3 2026 results briefing Hengtong said it will deepen internal synergies and resource integration within its biotech unit to boost product competitiveness, and will monitor external niche technology and product opportunities, focusing on key industry‑chain links and emerging technologies, with opportunistic partnerships or investments to complete its industry layout.